科尔普兰特在小规模医疗公司的比较中, 超过了Envoy Medical, 收入, 利和波动性更低. CollPlant outperforms Envoy Medical in small-cap medical company comparison, with higher revenue, earnings, and lower volatility.
在小规模医疗公司的比较中,CollPlant Biotechnologies (CLGN) 的表现优于Envoy Medical (COCH),收入,收益和β值较高. CollPlant Biotechnologies (CLGN) outperforms Envoy Medical (COCH) in a comparison of small-cap medical companies, with higher revenue, earnings, and a lower beta. Colplant拥有21.7%的机构所有权和0.24贝塔,比S&P 500低76%的波动性。 CollPlant has 21.7% institutional ownership and a beta of 0.24, suggesting 76% less volatility than the S&P 500. 另一方面,Envoy Medical的机构所有权为8.6%,贝塔值为2.29,表示波动率增加了129%. In contrast, Envoy Medical has 8.6% institutional ownership and a beta of 2.29, indicating 129% more volatility. 科尔普兰特生物技术公司的共识价格目标为11.00美元,表明潜在的上率为152.29%,而Envoy医疗公司的目标是7.25美元,潜在的上率为220.80%. CollPlant Biotechnologies has a consensus price target of $11.00, suggesting a potential upside of 152.29%, while Envoy Medical has a target of $7.25 and a potential upside of 220.80%. 然而，分析人士认为，Envoy Medical更高的上涨潜力使其更具优势。 However, analysists believe Envoy Medical's higher upside potential makes it more favorable.